- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02914327
Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
A Phase 1, Open-label Study of SNX-5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase
Studieöversikt
Detaljerad beskrivning
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults and is not considered curable outside of allogeneic stem cell transplantation.
BTK is a critical kinase in the B cell receptor signaling pathway. This pathway is amplified in CLL and results in amplification of proliferation and anti-apoptotic signals. By inhibiting BTK, ibrutinib eliminates the activation of these pro-survival pathways and microenvironment survival signals. While response to ibrutinib has been high with therapy well-tolerated overall, some patients have relapsed while others have been taken off therapy for toxicity or other reasons. Relapse in CLL can be mediated by at least two separate mechanisms. One is by mutations in BTK, which both decrease ibrutinib's affinity for BTK, and also changes the binding from irreversible to reversible. This is a proof of concept study to investigate whether the addition of SNX-5422 to an established dose of ibrutinib will reduce mutated BTK from CLL cells and/or prevents or delays disease progression of subjects with CLL.
This is an open-label study of SNX-5422 combined with ibrutinib. In each 28 day cycle, SNX-5422 will be dosed in the morning once every other day for 21 days, followed by a 7-day drug-free period. Subjects will continue to receive daily oral ibrutinib at their established dose level in the afternoon every day for 28 days. cycle
Studietyp
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43210
- Wexner Medical Center, Ohio State University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Males or non-pregnant, non-breastfeeding females 18 years-of-age or older
- A diagnosis of CLL as defined by IWCLL 2008 criteria and currently on treatment with ibrutinib without evidence of disease progression.
- No more than 4 prior lines of anti leukemia therapy (not including ibrutinib)
- Presence of mutated BTK in ≥ 4% of peripheral blood or bone marrow CLL cells, or ≥1% and rising on two separate measurements obtained at least 28 days apart.
- Life expectancy of at least 9 months
- Karnofsky performance score 70
- Adequate baseline laboratory assessments
- Signed informed consent form
- Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1 with the exception of alopecia
- Subjects with reproductive capability must agree to practice adequate contraception methods.
Exclusion Criteria:
- Subjects experiencing toxicity with ibrutinib
- Prior treatment with any Hsp90 inhibitor.
- Major surgery or significant traumatic injury within 4 weeks of starting study treatment.
- Conventional chemotherapy or radiation within 4 weeks.
- The need for treatment with medications with clinically-relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422
- Screening ECG QTc interval 470 msec for females, 450 msec for males.
- At increased risk for developing prolonged QT interval unless corrected to within normal limits prior to first dose of SNX-5422
- Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.
- Gastrointestinal diseases or conditions that could affect drug absorption
- Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis.
- History of documented adrenal dysfunction not due to malignancy.
- History of chronic liver disease.
- Active hepatitis A or B.
- Current alcohol dependence or drug abuse.
- Use of an investigational treatment (except for ibrutinib) from 30 days prior to the first dose
- Glaucoma, retinitis pigmentosa, macular degeneration, or any retinal changes detected by ophthalmological examination that are considered clinically important by examiner.
- Psychological or social reasons that would hinder or prevent compliance with the requirements of the protocol or compromise the informed consent process.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: SNX-5422 plus ibrutinib
Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle.
Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
|
SNX-5422 kapsel(er) doserad varannan dag i 21 dagar av en 28-dagars behandlingscykel till en total dos på 56 mg/m2 SNX-5422.
Försökspersonerna kommer att administrera dagligt oralt ibrutinib på eftermiddagen med minst 8 timmars mellanrum från SNX-5422 under 28 dagar av varje cykel.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Efficacy of the combination of SNX-5422 and ibrutinib
Tidsram: Every 12 weeks up to 52 weeks
|
Change in percent of mutated BTK in CLL cells
|
Every 12 weeks up to 52 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Antal försökspersoner som rapporterar biverkningar
Tidsram: Dag 28 i varje 4-veckorscykel från randomisering upp till 52 veckor
|
Frekvens och svårighetsgrad av biverkningar
|
Dag 28 i varje 4-veckorscykel från randomisering upp till 52 veckor
|
Time to disease progression
Tidsram: Up to 52 weeks
|
Elapsed time for each subject from randomization to relapse of disease up to 52 weeks
|
Up to 52 weeks
|
Clinical Laboratory testing
Tidsram: Day 28 of each 4 week cycle from randomization up to 52 weeks
|
Absolute values and changes from baseline for each subject using standard clinical chemistry, hematology and urinalysis parameters
|
Day 28 of each 4 week cycle from randomization up to 52 weeks
|
Electrocardiogram
Tidsram: Pre-dose on Day 1 of each 4 week cycle from randomization up to 52 weeks
|
Digital 12-lead ECG using standard recording methods at trough drug levels.
All ECG recordings will be analyzed for PR, RR, QT intervals, and for morphology.
|
Pre-dose on Day 1 of each 4 week cycle from randomization up to 52 weeks
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- SNX-5422-CLN1-011
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på SNX-5422 plus ibrutinib
-
Esanex Inc.AvslutadCancerFörenta staterna
-
Esanex Inc.Avslutad
-
Esanex Inc.Avslutad
-
Esanex Inc.Pfizer; Serenex, Inc.Avslutad
-
National Cancer Institute (NCI)Avslutad
-
Esanex Inc.Serenex, Inc.AvslutadHematologiska neoplasmerFörenta staterna
-
Esanex Inc.National Cancer Institute (NCI)AvslutadLymfom | Leukemi | Fast tumörmalignitet | Lymfoid malignitet (lymfom och KLL)Förenta staterna
-
Esanex Inc.Avslutad
-
Esanex Inc.Avslutad